Bill Detail
H.R. 1525
Congress: 119
Title
Protecting Life from Chemical Abortions Act
Summary
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
Sponsor
Rep. Kevin Hern [R-OK-1]
Status
Referred to the House Committee on Energy and Commerce.
Status as of Nov 13, 2026, 7:25 AM · synced 3d ago
Introduced
2025-02-24
Data source mode: congress-gov
Bill Engagement
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone.
Limited preview · paid intelligence
Keep the intelligence current—not just this one record.
Pulse currently has no matching linked lobbying filings for this bill and Congress. Federal Intelligence provides the broader research platform; purchasing access does not guarantee missing records or a bespoke bill watch.
Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.
SEE A FINISHED HEALTHCARE EXAMPLE
Three days of Hill visits. Two Medicare access questions.
A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.
Read the finished healthcare brief →After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.